Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T
The Journal of Clinical Endocrinology & Metabolism · 21.01.2025 · 110 (2) · e218-e230
DOI: 10.1210/clinem/dgae502 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 25.07.2024. Verfasst von Johannes Lahring und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Kidney, Liver and Metabolic Diseases, Pediatric Research Center, Hannover Medical School, D-30625 Hanover, Germany. Hauptthemen laut MEDLINE: Cystinosis, Renal Insufficiency, Chronic, Bone Diseases, Metabolic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Chiesi, Cystinose-Stiftung.
Abstract (Originalsprache)
Context
The pathophysiology of cystinosis-associated metabolic bone disease is complex.
Objective
We hypothesized a disturbed interaction between osteoblasts and osteoclasts.
Methods
This binational cross-sectional multicenter study included 103 patients with cystinosis (61% children) with chronic kidney disease (CKD) stages 1 to 5D/T at hospital clinics. Ten key bone markers were evaluated.
Results
Skeletal complications occurred in two-thirds of the patients, with adults having a 5-fold increased risk compared with children. Patients with CKD stages 1 to 3 showed reduced z-scores for serum phosphate and calcium and suppressed fibroblast growth factor 23 (FGF23) and parathyroid hormone levels, in conjunction with elevated bone-specific alkaline phosphatase levels. Serum phosphate was associated with estimated glomerular filtration rate, combined phosphate and active vitamin D treatment, and native vitamin D supplementation, while serum calcium was associated with age and dosage of active vitamin D. Sclerostin was generally elevated in children, and associated with age, FGF23 levels, and treatment with active vitamin D and growth hormone. The osteoclast marker tartrate-resistant acid phosphatase 5b was increased, and associated with age and treatment with active vitamin D. The ratio of soluble ligand of receptor activator of nuclear factor-κB (sRANKL) and osteoprotegerin (OPG), a surrogate for the regulation of osteoclastogenesis by osteoblasts, was decreased and associated with phosphate and 1,25(OH)2D3 levels. These changes were only partly corrected after transplantation.
Conclusion
Bone health in cystinosis deteriorates with age, which is associated with increased osteoclast activity despite counter-regulation of osteoblasts via OPG/RANKL, which in conjunction with elevated sclerostin levels and persistent rickets/osteomalacia, may promote progressive bone loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Kidney, Liver and Metabolic Diseases, Pediatric Research Center, Hannover Medical School, D-30625 Hanover, Germany.
- Department of Pediatric Orthopedics, Schoen Clinic München Harlaching, D-81547 Munich, Germany.
- Socialpediatric Center, Clinic Traunstein, Kliniken Südostbayern AG, D-83278 Traunstein, Germany.
- Division of Pediatric Nephrology, University Children's Hospital Hamburg, D-20251 Hamburg, Germany.
- Department of Pediatrics II, University Hospital Essen, D-45152 Essen, Germany.
- Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, D-13353 Berlin, Germany.
ORCID-Profile: Maren Leifheit-Nestler, Dieter Haffner
Förderung
- Chiesi
- Cystinose-Stiftung
Zitieren
APA
Lahring, J., Leifheit-Nestler, M., Ewert, A., Herzig, N., Köppl, C., Pott, V., Oh, J., Büscher, A., Thumfart, J., Weber, L. T., Arbeiter, K., Acham-Roschitz, B., Tönshoff, B., Zivicnjak, M., Hohenfellner, K., & Haffner, D. (2025). Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T. The Journal of Clinical Endocrinology & Metabolism, 110(2), e218-e230. https://doi.org/10.1210/clinem/dgae502
Vancouver
Lahring J, Leifheit-Nestler M, Ewert A, Herzig N, Köppl C, Pott V, et al. Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T. The Journal of Clinical Endocrinology & Metabolism. 2025;110(2):e218-e230. doi:10.1210/clinem/dgae502
BibTeX
@article{Lahring2025,
author = {Lahring, Johannes and Leifheit-Nestler, Maren and Ewert, Annika and Herzig, Nadine and Köppl, Christian and Pott, Veronika and Oh, Jun and Büscher, Anja and Thumfart, Julia and Weber, Lutz T and Arbeiter, Klaus and Acham-Roschitz, Birgit and Tönshoff, Burkhard and Zivicnjak, Miroslav and Hohenfellner, Katharina and Haffner, Dieter},
title = {Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {2},
pages = {e218--e230},
doi = {10.1210/clinem/dgae502}
}
EUVIMED